Genprex (GNPX) Hits New 1-Year Low at $1.50

Genprex Inc (NASDAQ:GNPX)’s share price reached a new 52-week low on Thursday . The stock traded as low as $1.50 and last traded at $1.54, with a volume of 150 shares trading hands. The stock had previously closed at $1.55.

Separately, Maxim Group began coverage on shares of Genprex in a report on Friday, September 14th. They set a “buy” rating and a $5.00 target price for the company.

TRADEMARK VIOLATION WARNING: This report was reported by Stock Observer and is the property of of Stock Observer. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at

Genprex Company Profile (NASDAQ:GNPX)

Genprex, Inc, a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome.

Recommended Story: Why do companies engage in swaps?

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with's FREE daily email newsletter.

Leave a Reply